https://www.mddionline.com/sites/all/themes/penton_subtheme_mddionline/images/logos/footer.png
mddionline.com
10 of the Most Anticipated New Medical Devices
Amanda Pedersen Aug 13, 2021

1 10

X

1 10

ADVERTISEMENT
Senseonics' Eversense XL
Graphic by Amanda Pedersen/MD+DI

Senseonics expects to receive approval for its Eversense 180-day pre-market approval supplement by the end of the year. The company submitted the PMA supplement in October 2020.

The PMA supplement application is being supported by soon-to-be published data from the PROMISE study. The submission was assigned to a lead FDA reviewer on April 15.

If approved, the continuous glucose monitor (CGM) would be approved for 180 days of use, as opposed to the current 90-day indication.

Next Up
Medical Design Excellence Awards 2022 Finalists: Cardiovascular Devices
Start Slideshow ›